Actelion Looks Within as Competition Lifts Drug Prices

Actelion Ltd. is depending on in-house research to invent new medicines because the company can’t compete with bigger rivals to buy products in development elsewhere, Chief Executive Officer Jean-Paul Clozel said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.